EP2288348A1 - Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion - Google Patents
Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesionInfo
- Publication number
- EP2288348A1 EP2288348A1 EP09749632A EP09749632A EP2288348A1 EP 2288348 A1 EP2288348 A1 EP 2288348A1 EP 09749632 A EP09749632 A EP 09749632A EP 09749632 A EP09749632 A EP 09749632A EP 2288348 A1 EP2288348 A1 EP 2288348A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- selectin
- oso
- nanoparticle according
- group
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to functionalized nanoparticles inhibiting selectin-mediated cell adhesion and their use as anti-inflammatory therapeutics. More specifically, said functionalized nanoparticles comprise a core, formed by gold, a shell coating said core, formed by a monolayer of a linker molecule, and an acyclic or carbocyclic sulfated amino alcohol linked to said linker molecule via a peptide bond.
- a functionalized nanoparticle comprising a core, formed by gold, a shell coating said core, formed by a monolayer of a linker molecule, and an acyclic or carbocyclic sulfated amino alcohol linked to said linker molecule via a peptide bond.
- said core has a diameter ⁇ 50 run, preferably ⁇ 25 run, more preferably ⁇ 15 run.
- said linker molecule is a linear or branched, preferably a linear alkyl chain, with at least one binding functionality for the attachment of said linker molecule to said core.
- said alkyl chain has 5 to 26 C-atoms, preferably 10 to 26 C-atoms.
- said binding functionality comprises at least one sulfur atom.
- said binding functionality is selected from the group comprising thiol (SH), thiolate (S " ) and disulfide (S 2 ).
- said acyclic or carbocyclic sulfated amino alcohol has the general formula wherein
- Ri and R 2 are independently selected from the group comprising H and molecules having the general formula with m and n being integer numbers between and including 1 and 3,
- n being an integer number between and including 1 and 5
- Xi and X 2 being independently selected from the group comprising H, OSO 3 " , and CH 2 OSO 3 ' ,
- Xi, X 2 , X 3 , and X 4 being independently selected from the group comprising H, OSO 3 " , and CH 2 OSO 3 ' , and
- Ri and R 2 comprises at least one sulfated alcohol group selected from
- said acyclic or carbocyclic sulfated amino alcohol is acyclic and preferably selected from the group comprising sulfated ethanolamine, sulfated serinol, and sulfated tromethamine.
- said linker molecule is represented by the formula wherein
- Z represents a binding functionality as defined above, preferably selected from the group comprising SH, S " , and S 2 , p is 4-12, and Gi is an acyclic or carbocyclic sulfated amino alcohol, preferably an acyclic or carbocyclic sulfated amino alcohol as defined above.
- the objects of the present invention are also solved by a method for producing a functionalized nanoparticle as defined above, comprising the linking of a sulfated amino alcohol via a peptide bond to linker molecules bound to a gold core.
- the objects of the present invention are also solved by a nanoparticle as defined above for the treatment of diseases.
- the objects of the present invention are also solved by the use of a nanoparticle as defined above for the production of a medicament for the treatment of inflammatory diseases.
- said inflammatory diseases are chronic inflammatory diseases, in particular rheumatoid arthritis, asthma, and psoriasis.
- said inflammatory diseases are ischemia reperfusion damages or graft repulsion.
- the nanoparticle as defined above is used as inhibitor of L-selectin and/or P-selectin and/or E-selectin.
- the term "functionalized nanoparticle” as used herein is meant to refer to a nanoparticle that is provided with (or coordinated with) functional groups or molecules that allow the binding to a specific target, such as a protein, preferably a specifically selected protein, such as a selectin, e.g. an L-, P-, or E-selectin, or a nanoparticle that is provided with functional groups or molecules that increase the stability of the nanoparticle in a given environment, e.g. by preventing aggregation.
- the term "core” as used herein is meant to refer to a core or nucleus that provides a base for the attachment of linker molecules via functional groups, such as thiol groups.
- shell as used herein is meant to refer to a shell covering the above-defined core and being formed by a monolayer, preferably a closed monolayer of a plurality of linker molecules.
- a core with a diameter of 6 run is coated by a monolayer formed by approximately 1300 linker molecules.
- linker molecule as used herein is meant to refer to a molecule, which is able to bind to the above-defined core via at least one terminal or non-terminal binding functionality, such as a thiol group, and which is provided with at least one additional polar functional group, that allows for binding to a target protein, such as selectin.
- selectin inhibitor as used herein is meant to refer to exogenous molecules or compounds, such as the nanoparticles described herein, that are able to bind to selectins with high affinity, thereby disrupting or preventing physiological selectin-ligand interactions.
- the inventors have surprisingly found that functionalized nanoparticles according to the present invention are excellent inhibitors of selectin-ligand interactions. With half inhibitory concentrations (IC 50 ) in the low picomolar range, they have a far higher affinity for selectins than any other known selectin inhibitor. By efficiently inhibiting selectin-ligand interactions, which in turn mediate the interaction between leukocytes and endothelial cells, the functionalized nanoparticles according to the present invention could provide a potent way of treating a variety of inflammatory diseases.
- Nanoparticles according to the present invention i.e. comprising an acyclic or carbocyclic sulfated amino alcohol
- the covalent linking of the acyclic or carbocyclic sulfated amino alcohols to the linker molecules of the shell via peptide bonds provides for hydrolytic stability.
- the inventors show that the functionalized nanoparticles according to the present invention are non-toxic for living cells.
- Figure 1 is a schematic illustration of the interactions between endothelial and leukocyte adhesion molecules during leukocyte adhesion. Circles highlight selectin-ligand interactions;
- Figure 2 shows the syntheses of various functionalized gold nanoparticles.
- Figure 2A shows the synthesis of gold colloids covered/coordinated with N-hydrosuccinimid-11- mercaptoundecanoate
- Figure 2B shows the synthesis of ethanolamine-coordinated Au- colloids
- Figure 2C shows the sulfation of ethanolamine-coordinated Au-colloids
- Figure 2D shows the synthesis of serinol-coordinated Au-colloids
- Figure 2E shows the sulfation of serinol-coordinated Au-colloids
- Figure 2F shows the synthesis of tromethamine-coordinated Au-colloids
- Figure 2G shows the sulfation of tromethamine-coordinated Au-colloids
- Figure 2G shows the sulfation of tromethamine-coordinated Au-colloids
- Figure 3 is a graph showing the in vitro inhibition of L-selectin/P-selectin-ligand interaction by functionalized gold (Au)-colloids according to the present invention, as determined by surface plasmon resonance (SPR);
- Table 1 shows the half inhibitory concentrations (IC 50 ) of three different functionalized nanoparticles according to the present invention for both L-selectin and P-selectin;
- Table 2 shows the vitality of cells treated with various concentrations of serinol-disulfate- functionalized Au-nanoparticles.
- Example 1 Au-colloids coordinated with N-hydroxysuccinimid-l l-mercaptoundecanoate
- the nanoparticle solution was dialysed against DMF (MWCO: 4000-6000, three times for 3 h with 200 ml of DMF), dried under vacuum and resolved in 5 ml of anhydrous DMF (Figure 2D).
- Example 8 In vitro inhibition of selectin-ligand interaction using functionalized colloidal gold nanoparticles
- Selectin-ligand binding was analyzed by surface plasmon resonance (SPR). First, the binding (detected as resonance units) of selectin-coated nanoparticles to a selectin ligand, immobilized on a sensor chip, was tested, and the resulting signal was henceforth referred to as 100% binding. Preincubation of the selectin-coated particles with varying concentrations of a selectin inhibitor decreased the binding signal. The calculated IC 50 value (half inhibitory concentration) is the molar concentration of the inhibitor needed to reduce the binding signal to 50% of the initial value.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09749632A EP2288348A1 (en) | 2008-05-21 | 2009-05-20 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08009414A EP2123269A1 (en) | 2008-05-21 | 2008-05-21 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
EP09749632A EP2288348A1 (en) | 2008-05-21 | 2009-05-20 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
PCT/EP2009/003614 WO2009141142A1 (en) | 2008-05-21 | 2009-05-20 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2288348A1 true EP2288348A1 (en) | 2011-03-02 |
Family
ID=39865006
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08009414A Withdrawn EP2123269A1 (en) | 2008-05-21 | 2008-05-21 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
EP09749632A Withdrawn EP2288348A1 (en) | 2008-05-21 | 2009-05-20 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08009414A Withdrawn EP2123269A1 (en) | 2008-05-21 | 2008-05-21 | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP2123269A1 (en) |
WO (1) | WO2009141142A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9949416B2 (en) | 2010-12-15 | 2018-04-17 | Advanced Bionics Ag | Protection for implanted gold surfaces |
DE102011101952A1 (en) | 2011-05-18 | 2012-11-22 | Charité - Universitätsmedizin Berlin | Nanoparticles functionalized with dendritic polyglycerol sulfate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0025414D0 (en) * | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US7998672B2 (en) * | 2006-05-30 | 2011-08-16 | The University Of Utah Research Foundation | Simultaneous amplification and detection of ribonucleic acid be an optical method using surface plasmon resonance |
EP2033660A1 (en) * | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
-
2008
- 2008-05-21 EP EP08009414A patent/EP2123269A1/en not_active Withdrawn
-
2009
- 2009-05-20 WO PCT/EP2009/003614 patent/WO2009141142A1/en active Application Filing
- 2009-05-20 EP EP09749632A patent/EP2288348A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2009141142A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009141142A8 (en) | 2010-11-04 |
WO2009141142A1 (en) | 2009-11-26 |
EP2123269A1 (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5274248B2 (en) | Nitric oxide releasing particles for nitric oxide therapy and biomedical applications | |
EP2033660A1 (en) | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion | |
Hu et al. | Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells | |
US20140363507A1 (en) | Dentric polyglycerol sulfates and sulfonates and their use for inflammatory diseases | |
JP5539733B2 (en) | Self-assembling amphiphilic polymers as antiviral drugs | |
WO2012104831A1 (en) | Surface-modified heavy metal nanoparticles, compositions and uses thereof | |
JP2022510986A (en) | Hyaluronic acid and epigallocatechin-3-O-gallic acid conjugates and nanoparticles and their use | |
Tao et al. | Paclitaxel-loaded tocopheryl succinate-conjugated chitosan oligosaccharide nanoparticles for synergistic chemotherapy | |
Fang et al. | Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia | |
Ehsanimehr et al. | Synthesis of pH-sensitive nanocarriers based on polyacrylamide grafted nanocrystalline cellulose for targeted drug delivery to folate receptor in breast cancer cells | |
Khatri et al. | Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells | |
CN112089845A (en) | Taxane drug-adriamycin prodrug self-assembly nanoparticles and application thereof | |
US20040213757A1 (en) | Water soluble wortmannin derivatives | |
US20130266518A1 (en) | Methods and Compositions for Using Bleomycin-Derivatized Microbubbles | |
EP2123269A1 (en) | Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion | |
Han et al. | Bioenzyme-responsive l-arginine-based carbon dots: the replenishment of nitric oxide for nonpharmaceutical therapy | |
Liu et al. | Mouse model to explore the therapeutic effect of nano-doxorubicin drug delivery system on bladder cancer | |
CN117414435A (en) | Aptamer coupling drug and application thereof | |
CN103180333A (en) | Glycodendrimers of polypropyletherimine | |
US20100323021A1 (en) | Antitumoral treatments | |
KR20190075389A (en) | Pharmaceutical composition comprising a nanostructure carrying an anticancer drug for treating liver cancer | |
CN112245590A (en) | Sulphonylated betaine-modified adriamycin derivative, nano-drug and preparation method thereof | |
Liu et al. | Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer | |
CN118027128A (en) | Dexamethasone-linolenic acid prodrug self-assembled nanoparticle for synergistic treatment of inflammation and application thereof | |
CN114276390A (en) | Dithiocarbamate derivative nano-drug for delivering antitumor drug as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101110 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROSKAMP, MEIKE Inventor name: REISSIG, HANS-ULRICH Inventor name: DERNEDDE, JENS Inventor name: SCHLECHT, SABINE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130622 |